Generated by AI
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release therapies designed for ophthalmic use. Its current portfolio includes a marketed product for post-surgical ocular inflammation and pain, along with investigational therapies targeting retinal diseases, glaucoma, ocular hypertension, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix’s products and pipeline are centered on improving drug delivery in ophthalmology, where longer-acting formulations can help address treatment burden and support more consistent therapy administration. Based in Bedford, Massachusetts, the company operates in the specialty biopharmaceutical market with a strong emphasis on ocular care and retinal disease management.
Website14 Crosby Drive
Bedford, MA, 01730
United States
The latest articles about OCUL.
Ocular Therapeutix detailed its outlook during the UBS Global Biopharma Conference in London.
What Ocular Therapeutix’s latest earnings reveal Ocular Therapeutix (OCUL) paired a high profile clinical milestone for AXPAXLI in wet AMD with fresh quarterly numbers. This gives a clearer picture of how the story looks on both science and cash flow. On the financial side, the firm reported Q3 2026 revenue of US$12.87 million, compared with US$14.54 million a year earlier, and a net loss of US$94.78 million, wider than the prior US$69.42 million loss. Over the first nine months of 2026,...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about OCUL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.